icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
San Francisco
November 2018
Back grey_arrow_rt.gif
GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis
  Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Michael Charlton,1 Michelle Lai,2 Mazen Noureddin,3 Jacqueline M. Tarrant,4 Lulu Wang,4 Tuan Nguyen,4 Bryan J. McColgan,4 Chuhan Chung,4 Scott D. Patterson,4 Robert P. Myers,4 Parvez Mantry,5 Peter J. Ruane,6 Rohit Loomba7 1University of Chicago, IL; 2Beth Israel Deacones
s Medical Center and Harvard Medical School, Boston, MA; 3Cedars-Sinai Medical Center, Los Angeles, CA; 4Gilead Sciences, Inc., Foster City, CA; 5The Liver Institute at Methodist Dallas, TX; 6Ruane Clinical Research Group, Inc., Los Angeles, CA; 7UC San Diego, La Jolla, CA







ACCi, ACC inhibitor; CPT1, carnitine palmitoyltransferase I; FASN, fatty-acid synthase; SCoa, succinyl-CoA
References: 1. Peng K-Y, et al. J Lipid Res 2018;59:1977-86; 2. Loomba R, et al. Gastroenterology. 2018 Sept 14 [in press; https://www.ncbi.nlm.nih.gov/pubmed/30059671]; 3. Lawitz E, et al. EASL 2017, abstr GS-009; 4. Patel J, et al. Ther Adv Gastroenterol 2016; 9:692-701.